Adipotide
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Adipotide (FTPP / prohibitin-targeting peptide) is a pro-apoptotic peptidomimetic developed at MD Anderson Cancer Center. It’s mechanistically unlike everything else in the fat-loss / exercise-mimetic peptide family: it doesn’t nudge metabolism, it’s designed to destroy fat tissue’s blood supply. thepeptidelist.com files it under weight-loss.
Where compounds like AOD-9604, HGH Fragment 176-191, AICAR, and SLU-PP-332 work by nudging lipolysis, AMPK, or ERR signaling, Adipotide is a blunt instrument: it kills the blood vessels feeding fat tissue outright. That mechanism is the source of both its dramatic preclinical effect and its serious safety problem.
What does it do in my body?
Per thepeptidelist.com: targets prohibitin on the blood vessels supplying white adipose tissue, potentially disrupting blood supply to fat cells and triggering apoptosis (programmed cell death).
It’s a two-part molecule: a homing peptide that recognizes prohibitin-1 on the vasculature feeding white fat, fused to a pro-apoptotic sequence. Where it binds, it kills the local blood vessels, and the fat tissue they fed dies off. Powerful in concept — and the same blunt-instrument mechanism is the source of the safety problem below.
How can it help me?
- Where the science stands: Preclinical primate fat-mass reduction only; 0 studies cited, 0 human trials per thepeptidelist.com
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
This is the one compound in the metabolic-peptide family with a real, serious safety concern, and it should not be softened.
- Documented nephrotoxicity (kidney damage) in the primate trial that demonstrated fat-mass reduction. The same mechanism that kills fat-tissue blood vessels also appears to damage the kidney’s dense vasculature. This is a primary, mechanism-intrinsic safety signal — not a theoretical concern.
- No human safety data exists at all. There is no dose, no protocol, and no monitoring framework that would make human use of Adipotide a defensible proposition based on current evidence.
- 0035 grading explicitly states “never recommended” for this compound, driven directly by the nephrotoxicity finding.
There is no management strategy offered here because none is warranted — the honest position on Adipotide is that the safety signal is the headline, and the mechanism that makes it effective in animals is the same mechanism that damaged kidneys in the trial that proved it works.
Regulatory status: research_only, not FDA-approved, not eligible for compounding. OHM grade: D / RED / provisional: “never recommended” in the source grading, driven by the preclinical nephrotoxicity signal. For a verified-vendor fat-loss peptide with strong human safety and efficacy data, see Retatrutide.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
No human protocol exists — and given the primate nephrotoxicity signal and total absence of human data, none should be inferred. Encyclopedia-only.
What should I avoid combining — and what's synergistic?
Adipotide doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
A pro-apoptotic peptidomimetic designed to destroy the blood supply to fat tissue — with real, documented primate kidney toxicity and zero human trials. This is the cautionary edge of the fat-loss-peptide map, and the safety signal here is not a footnote.
| Class | Pro-apoptotic targeting peptidomimetic (FTPP / prohibitin-targeting peptide) |
| Mechanism (one line) | Targets prohibitin-1 on blood vessels feeding white adipose tissue, disrupting blood supply and triggering apoptosis (programmed cell death) in fat tissue |
| Evidence base | Preclinical primate fat-mass reduction only; 0 studies cited, 0 human trials per thepeptidelist.com |
| Safety record | RED FLAG — documented nephrotoxicity (kidney damage) signal in the same primate trial that showed fat loss. This is a real, mechanism-intrinsic toxicity finding, not a marketing-fear overlay |
| Regulatory status | research_only; not FDA-approved; not eligible for compounding; OHM grade: D / RED / “never recommended” |
What it is
Adipotide (FTPP / prohibitin-targeting peptide) is a pro-apoptotic peptidomimetic developed at MD Anderson Cancer Center. It’s mechanistically unlike everything else in the fat-loss / exercise-mimetic peptide family: it doesn’t nudge metabolism, it’s designed to destroy fat tissue’s blood supply. thepeptidelist.com files it under weight-loss.
Where compounds like AOD-9604, HGH Fragment 176-191, AICAR, and SLU-PP-332 work by nudging lipolysis, AMPK, or ERR signaling, Adipotide is a blunt instrument: it kills the blood vessels feeding fat tissue outright. That mechanism is the source of both its dramatic preclinical effect and its serious safety problem.
How it works
Per thepeptidelist.com: targets prohibitin on the blood vessels supplying white adipose tissue, potentially disrupting blood supply to fat cells and triggering apoptosis (programmed cell death).
It’s a two-part molecule: a homing peptide that recognizes prohibitin-1 on the vasculature feeding white fat, fused to a pro-apoptotic sequence. Where it binds, it kills the local blood vessels, and the fat tissue they fed dies off. Powerful in concept — and the same blunt-instrument mechanism is the source of the safety problem below.
What the research shows
- Preclinical fat-mass reduction in monkeys — obese rhesus monkeys lost substantial weight and fat mass in the foundational primate work.
- thepeptidelist.com grades it Anecdotal — 0 studies cited on the profile, 0 human trials. Its evidence summary: “No published clinical studies were found on PubMed for ADIPOTIDE. Evidence is limited to preclinical research or community reports.”
- No human trials.
Safety flag — the reason this compound is graded RED
The primate trial that showed fat loss also showed a nephrotoxicity (kidney-damage) signal. That is not a footnote: it is the central fact about Adipotide. The mechanism that kills fat-tissue vasculature is not perfectly selective, and the kidney’s dense, high-flow vasculature appears to take collateral damage. Per the 0035 pass: “published nephrotoxicity signal in the primate trial… Safety red because of the preclinical nephrotoxicity signal.” (primary primate-study still to be pinned).
The honest read (OHM doctrine: surface the safety data as information, not fear-bait, but surface it loudly because it’s real): Adipotide is a fascinating mechanism with a documented, mechanism-intrinsic toxicity signal in primates and zero human data. It belongs in the encyclopedia as the cautionary edge of the fat-loss-peptide map. We don’t moralize, and the final call is Rick’s — but the nephrotoxicity signal is a genuine, primary safety fact, not a marketing-fear overlay, and any content that mentions Adipotide should carry it plainly.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice.
No human protocol exists — and given the primate nephrotoxicity signal and total absence of human data, none should be inferred. Encyclopedia-only.
Side effects & management
This is the one compound in the metabolic-peptide family with a real, serious safety concern, and it should not be softened.
- Documented nephrotoxicity (kidney damage) in the primate trial that demonstrated fat-mass reduction. The same mechanism that kills fat-tissue blood vessels also appears to damage the kidney’s dense vasculature. This is a primary, mechanism-intrinsic safety signal — not a theoretical concern.
- No human safety data exists at all. There is no dose, no protocol, and no monitoring framework that would make human use of Adipotide a defensible proposition based on current evidence.
- 0035 grading explicitly states “never recommended” for this compound, driven directly by the nephrotoxicity finding.
There is no management strategy offered here because none is warranted — the honest position on Adipotide is that the safety signal is the headline, and the mechanism that makes it effective in animals is the same mechanism that damaged kidneys in the trial that proved it works.
Regulatory status
research_only, not FDA-approved, not eligible for compounding. OHM grade: D / RED / provisional: “never recommended” in the source grading, driven by the preclinical nephrotoxicity signal. For a verified-vendor fat-loss peptide with strong human safety and efficacy data, see Retatrutide.
Sources
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/RED/provisional: “never recommended”), including the primate fat-mass-reduction finding and the nephrotoxicity signal.
Related: AOD-9604 · HGH Fragment 176-191 · AICAR · SLU-PP-332 · Retatrutide · Tesamorelin · MOTS-c.
Sources & references
- thepeptidelist.com directory profile; primary source for mechanism, evidence tier, and regulatory status (all site-derived citations carry per KB doctrine).
- OHM tier/safety grading (D/RED/provisional: “never recommended”), including the primate fat-mass-reduction finding and the nephrotoxicity signal.
Related: AOD-9604 · HGH Fragment 176-191 · AICAR · SLU-PP-332 · Retatrutide · Tesamorelin · MOTS-c.